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Cardiac remodeling after acute myocardial infarction is associated with ventricular dysfunction 
and deteriorates the prognosis. Remodeling consists of genetic and molecular changes in 
response to cardiac injury. This study tested the concentrations of mRNA transcripts in the 
peripheral blood of patients after myocardial infarction with and without cardiac remodeling. 
Our results revealed versican (VCAN) expression was lower in patients who developed left 
ventricular remodeling (LVR), compared to those who did not. Further studies are needed to 









Background: Adverse left-ventricular remodelling (LVR) is defined as an increase in end-
diastolic left-ventricular volume by 20% 6 months after acute myocardial infarction (AMI). 
LVR is associated with cardiac dysfunction, therefore deteriorating the prognosis.  
Aims: We aimed to compare the concentrations of messenger RNA transcripts in the peripheral 
blood of patients with and without LVR at 6 months. 
Methods: The study included 75 patients with first ST-elevation myocardial infarction 
(STEMI) treated with percutaneous coronary intervention. Whole blood concentrations of 6 
transcripts were determined 24 hours after AMI using droplet digital polymerase chain reaction. 
The correlations between mRNA transcript expression and left ventricular ejection fraction 
(LVEF) and N-terminal-pro B type natriuretic peptide (NT-proBNP) concentration were 
evaluated.  
Results: Among 75 patients, 4 were lost to follow-up and 71 were included in the analysis. 
Seventeen (24%) patients developed LVR at 6 months. Versican (VCAN) mRNA expression 
was lower in patients who developed LVR, compared to those who did not (P = 0.02), and 
discriminated between these patients (area under the ROC curve 67%; P = 0.04). Expression of 
VCAN transcript <75.3 normalized units predicted LVR with 71% sensitivity and 67% 
specificity. In a multivariable regression analysis, VCAN expression remained the only 
independent predictor of LVR (OR 3.475; 95% CI, 1.000–12.075; P = 0.04).  
Conclusions: Dysregulation of VCAN expression in the acute phase of AMI may contribute to 
LVR at 6 months. Whether decreased expression of VCAN might be a useful tool to predict 
LVR in clinical practice remains to be established. 
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INTRODUCTION 
Heart failure (HF) is an important public health challenge, with a global appearance of 1%–2% 
of the adult population, increasing to 10% among people over 70 years of age [1]. Acute 
myocardial infarction (AMI) is responsible for over 50% of cases of HF [2]. In patients with 
AMI, the loss of contractile tissue and left ventricular remodelling (LVR) is anticipated by the 
structural and functional alterations of the left ventricle, including fibrosis and inflammation 
[3]. The most common definition of LVR, applied also in this study, is an increase in left-
ventricular end-diastolic volume (LVEDV) by 20% 6 months after AMI [4]. LVR affects 25% 




parameters increasing the risk of LVR after AMI include the extension and anterior location of 
AMI, late or unsuccessful revascularization [6], high concentrations of natriuretic peptides and 
cardiac troponins [7] and enlarged left ventricle (LV) on echocardiography [8]. However, at 
present there are no reliable biomarkers to predict cardiac remodeling. Due to the role in the 
development of adverse cardiac remodeling after AMI, novel markers including microRNA and 
messenger RNA (mRNA) transcripts might be superior to the currently available biomarkers of 
heart failure and cardiac remodeling, such as N-terminal-pro B type natriuretic peptide (NT-
proBNP). Hence, identification of the crucial genes involved in the process of remodeling and 
associated mRNA transcripts might help to individualize the treatment strategy, improve 
cardiovascular risk stratification and prediction of outcomes [9]. 
mRNA is a single-stranded molecule of ribonucleic acid that corresponds to the sequence of a 
gene and is read in the process of translation (synthesizing a protein) [10]. Previously, we 
showed that the expression of mRNA transcripts is altered in the peripheral blood of patients 
after AMI, compared to controls [11]. Using genome-wide gene expression profiling, we 
selected several transcripts involved in the development of HF after AMI. Here, we 
hypothesized that the post-AMI expression of mRNA differs in patients with and without LVR. 
We compared the level of selected mRNA transcripts in patients after AMI with and without 




We designed an investigator-initiated, prospective study, conducted at the 1st Chair and 
Department of Cardiology, Medical University of Warsaw, Poland in collaboration with the 
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland. The 
study protocol, designed in compliance with the Declaration of Helsinki, was approved by the 
Ethics Committee of Medical University of Warsaw (approval number: KB/176/2015). All 
participants provided written informed consent. The study design is showed in Figure 1A. 
 
Study participants 
Study inclusion and exclusion criteria are listed in Table 1. Patients were eligible for enrolment 
if they (a) were admitted to the hospital due to ST-segment elevation of acute myocardial 
infarction (STEMI), and (b) underwent percutaneous coronary intervention (PCI) with stent 
implantation. STEMI was diagnosed based on persistent ST-segment elevation of at least 0.1 





Clinical data collection 
At baseline, data regarding demographics (age, gender), body mass index, cardiovascular risk 
factors, routine laboratory parameters. All patients received standard treatment after STEMI 
according to the guidelines, including double antiplatelet therapy, β-blocker, angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker, aldosterone receptor antagonist 
and protein pump inhibitor [12]. 
The concentration of NT-proBNP was measured within 24 hours after AMI and at 6-month 
follow-up in whole blood sample. Transthoracic echocardiography was conducted within 24 
hours after AMI and repeated at the follow-up visit. LVR was defined as an increase in LVEDV 
by 20% at 6 months after AMI, compared to baseline echocardiography.  
 
Messenger RNA transcripts analysis 
Whole blood concentrations of 6 transcripts: Ribonuclease 1 (RNASE1), Jun dimerization 
protein 2 (JDP2), Cluster of differentiation 163 (CD163), Cytochrome P450 family 27 
subfamily A member 1 (CYP27A), Versican (VCAN), Interleukin type 1, receptor 2 (IL1R2) 
were determined within 24 hours after AMI using droplet digital polymerase chain reaction 
(ddPCR). Selection of specific transcripts was based on the results of our earlier study, which 
showed that the genes responsible for the expression of these transcript differ between patients 
with AMI and healthy controls, and between patients who developed post-infarct HF at 6 
months, vs those who did not [11]. In the past study, the expression of genes encoding the 
selected transcripts differed 2- to 3-fold between the groups (post-infarct HF vs no HF: RNASE1 
2.044-fold change; P = 0.002; JDP2 1.825-fold change; P = 0.001; CD163: 1.768-fold change, 
P = 0.003; IL1R2: 3.167-fold change; P = 0.008; AMI vs controls: CYP27A 1.712-fold change; 
P = 0.005; VCAN 1.16-fold change; P = 0.001). In the past study, we used both peripheral 
blood mononuclear cells and whole blood as the RNA source. The obtained results showed that 
the choice of material (whole blood vs peripheral blood mononuclear cells) and analytical 
method (microarrays vs RT-qPCR) does not affect the obtained results, indicating the 
robustness of the proposed approach. In the current research, using different cohort of patients 
and different methodology (ddPCR), we focused on the evaluation of previously selected 
mRNA transcripts in patients with and without LVR. Briefly, whole blood was collected into 
PAXgene Blood RNA tubes and total RNA was isolated using the PAXgene Blood RNA kit 
(Qiagen, Hilden, Germany). Reverse transcription was performed using 400 ng of total RNA 




Manager Professional Suite software, version 6.00 (Sci Ed Software, NC, USA). ddPCR was 
carried out using QX200™ Droplet Digital™ PCR System (Bio-Rad, CA, USA). The cDNA 
templates were diluted to a concentration of 4 ng/μl (total RNA equivalent) with nuclease-free 
water and 2 µl was assayed in a 22-µl reaction volume using EvaGreen (Bio-Rad) and thermal 
cycling conditions recommended for EvaGreen assays. After amplification, the plates were 
loaded into the QX200 Droplet Reader and the ddPCR results were analyzed with QuantaSoft 
software v.1.7.4.0917 and QuantaSoft Analysis Pro software v.1.0.596 (Bio-Rad). The absolute 
number of target molecules in the ddPCR reaction was determined using Poisson statistical 
analysis and background-corrected based on the no-template control. Data were expressed as 
normalized units, according to mRNA level of the reference gene HPRT1. In our study, we 
applied the droplet digital PCR approach to determine the mRNA expression level of studied 
genes. ddPCR fractionates templates into individual reaction systems, then transitional PCR are 
run in individual wells and DNA content can be quantitated by direct counting PCR positive 
percentage among all reactions. The use of absence and presence of signals to indicate target 
DNA makes a ‘digital’ direct measurement of samples. The digital PCR concept has many 
potential advantages over classical real-time PCR, including the capability to obtain absolute 
quantification without external references and robustness to variations.  
 
Endpoints 
The primary endpoint was the difference between the expression of mRNA transcripts after 
AMI in patients with and without LVR at 6 months. The secondary endpoint was the predictive 
value of mRNA transcripts for LVR at 6 months. 
 
Statistical analysis 
About 25% of patients after AMI develop LVR [5]. Since there are currently no data in the 
literature regarding the differences in mRNA transcript expression of the investigated genes in 
patients with and without LVR, our sample size calculation was based on the previous study, 
where we investigated gene expression in patients who did and did not develop post-infarct HR 
6 months after STEMI [11]. In this study, the expression of most genes differed 2- to 3-fold 
between the groups, resulting in the nominal difference of at least 1. Hence, the sample size 
was calculated based on the following assumptions: (I) significance level for two-sided testing 
0.05; (II) test power 0.8; (III) standard deviation ± 1; (IV) estimated difference in mean 




the study should include at least 17 patients who will develop LVR (25% of the group). 
Assuming 10% of patients lost to follow-up, the required sample size was 75 patients. 
Statistical analysis was conducted using IBM SPSS Statistics, version 27.0 (IBM). Categorical 
variables were presented as number and percent and compared using Fischer's exact test. A 
Shapiro–Wilk test was used to assess normal distribution of continuous variables. Continuous 
variables were presented as mean (SD) or median with interquartile range. Correlations were 
analyzed using a Spearman correlation coefficient test. Transcript expression were compared 
between the groups using an unpaired t-test or Mann-Whitney U test. The diagnostic ability of 
mRNA transcripts to discriminate between patients with and without LVR and the cut-offs were 
calculated using a receiver operating characteristic (ROC) curve. For analysis of LVR 
predictors, univariable logistic regression analysis was used. Next, multivariable analysis was 
performed, where LVR was used as a dependent variable and predictors which were significant 
in univariable analysis were used as independent variables. Results were expressed as odds ratio 
(OR) and 95% confidence interval (CI). Mortality and other adverse events were reported 
descriptively. A P value below 0.05 was considered significant.  
 
RESULTS  
The inclusion and exclusion chart are shown in Figure 1B. Between March 2015 and April 
2019, 74 patients with first STEMI treated with PCI provided informed written consent and 
were included in the study. 
 
Clinical data 
Among 75 patients, 4 were lost to follow-up and 71 were included in the analysis. Patient 
characteristics are shown in Table 2. Seventeen (24%) patients did and 54 patients (76%) did 
not develop LVR at 6 months. Patients with LVR were younger than patients without LVR 
(mean age, 56.0 [SD, 6.8] years vs 57.9 [SD, 11.4] years, respectively; P = 0.039). There were 
no other clinical differences between patients with and without LVR. Baseline 
echocardiography parameters and pharmacotherapy were comparable between the groups. All 
patients received dual antiplatelet therapy, all patients except for one received statin, and more 
than 88% of patients received a β-blocker and an angiotensin-converting enzyme inhibitor.  
At 6 months follow-up LVEDV was larger with patients with LVR, compared to those without 
LVR (P = 0.04). The LVEF was comparable in both groups. There were no deaths and only 





VCAN expression is an independent predictor of LVR 
Figure 2 shows the mRNA transcripts expression after AMI in patients with and without LVR 
at 6 months. VCAN expression was lower in patients who developed LVR, compared to those 
who did not (P = 0.02; Figure 2A), and discriminated between these patients (area under the 
ROC curve, 67%; P = 0.04; Figure 2B). The expression of other mRNA transcripts did not 
differ between the groups. Expression of VCAN transcript <75.3 normalized units predicted 
LVR with 71% sensitivity and 67% specificity. Statistical estimates for the prediction of LVR 
by VCAN expression, including the cut-off values determined based on the ROC curve, are 
showed in Table 3.  
To determine the clinical predictors of LVR, we performed univariable logistic regression 
analysis (Table 4). We found that VCAN expression level below the determined cut-off and 
age were the only predictors of LVR (OR, 4.050; 95% CI, 1.204–13.619; P = 0.024 for VCAN; 
OR, 0.944; 95% CI, 0.892–0.999; P = 0.047 for age). Next, we incorporated VCAN expression 
and age in the multivariable regression model. VCAN was the only independent predictor of 
LVR (OR, 3.475; 95% CI, 1.000–12.075; P = 0.047; Table 5).  
 
VCAN expression correlates with NT-proBNP concentration 
Figures 2C and 2D show the correlations between VCAN expression at 24 hours and NT-
proBNP and LVEF at 24 hours and 6 months after AMI. There was a trend towards a positive 
correlation between VCAN expression and NT-proBNP concentration at 24 hours (R = 0.23; P 
= 0.07) and an intermediate, positive correlation at 6 months (R = 0.33; P = 0.01). There were 
no correlations between VCAN expression and LVEF. 
 
DISCUSSION 
The main finding of our study is that decreased VCAN expression is an independent predictor 
of LVR after AMI, increasing the odds of LVR 3.5-fold. The second important finding is the 
positive correlation between VCAN expression and NT-proBNP concentrations in patients after 
AMI. 
VCAN is a protective proteoglycan regulating cell survival and extracellular matrix assembly 
[11]. Many studies demonstrated the role of VCAN in cardiac remodeling. For example, VCAN 
was showed to induce myofibroblast differentiation during lung remodeling [14]. In addition, 
human cardiomyocyte differentiation is accompanied by changes in the expression and 
accumulation of VCAN [15]. VCAN favors transforming growth factor β-mediated signaling 




Upregulation of VCAN in the infarcted myocardium mediates chemotaxis and cytokine release 
in animal model. The transient expression of VCAN by infiltrating monocytes in the infarcted 
area of the heart suggests the role of VCAN in the inflammatory response [17]. Furthermore, a 
post-mortem analysis of 20 infarcted cardiac muscles demonstrated the similar localization of 
the fragmented VCAN and ADAM metallopeptidase with thrombospondin type 1 motif 1 
(ADAMTS1) in the necrotic areas. ADAMTS1 is produced by infiltrating macrophages, 
suggesting that inflammatory processes after AMI lead to VCAN fragmentation [18]. 
Altogether, down-regulation of VCAN transcript expression in whole blood samples may be a 
sign of dysfunctional repair mechanisms after AMI, increasing the risk of LVR. 
NT-proBNP is an established biomarker of HF and the fragment of the brain natriuretic 
hormone (BNP) propeptide, which is released in response to the increased atrial and ventricular 
wall stretch [19]. BNP secretion counteracts the increased cardiac overload, resulting in 
vasodilation, diuresis, natriuresis and inhibition of cardiac remodeling [20]. The positive 
correlation between VCAN expression and NT-proBNP observed in our cohort indicated that, 
similarly to BNP, increased VCAN transcript level might be a protective mechanism in patients 
after AMI. Concurrently, dysregulated VCAN expression might be a sign of the compensatory 
mechanisms’ failure. However, since we only observed a correlation between both markers, 
without any causal relationship, we may only speculate about its pathophysiological relevance. 
 
Limitations 
The main limitation of our study is the single-centre design and relatively small sample size 
included in the analysis. Moreover, since our study was not powered for hard clinical end-points 
including hospitalizations or death due to HF, our results remain hypothesis-generating and 
required confirmation in future trials. Finally, the wide confidence interval of VCAN 
expression in the multivariable logistic regression model requires caution when interpreting the 
results. Altogether, our results should be confirmed in a larger, preferably multi-centre study 
before implementation in clinical practice. 
 
CONCLUSIONS 
In our cohort of patients after STEMI, low VCAN expression was an independent predictor of 
LVR at 6 months. Whether decreased expression of VCAN might be a useful tool to predict 
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Table 1. Eligibility criteria for the study  
Inclusion criteria Exclusion criteria 
• Age ≥18 years 
• Informed consent to participate in the 
study 
• ST-elevation myocardial infarction  
• PCI with stent implantation 
 
• Non-ST-elevation acute coronary 
syndrome  
• Cardiogenic shock 
• Severe chronic renal failure 
(eGFR <30 ml/min/1.73 m2) 
• Severe liver insufficiency 
(Child-Pugh class C) 
• Known pregnancy or breast-feeding 










Table 2. Main characteristics of patients with and without left ventricular remodelling (LVR) 
at 6 months after ST-elevation myocardial infarction 




Age, years, mean (SD) 56.0 (6.8) 57.9 (11.4) 0.039 
Male gender, n (%) 10 (59) 40 (74) 0.229 
BMI, mean (SD) 28.9 (4.3) 27.3 (4.3) 0.293 
Anterior AMI, n (%) 6 (35) 15 (36) 0.135 
Cardiovascular risk factors, n (%) 
    Arterial hypertension 8 (47) 29 (69) 0.413 
    Diabetes mellitus 3 (18) 15 (36) 0.845 
    Dyslipidemia 10 (59) 30 (71) 0.075 
    Smoking 6 (35) 26 (62) 0.908 
    Previous AMI 1 (6) 2 (5) 0.486 
Laboratory parameters at baseline 
    NT-proBNP, pg/ml, median (IQR) 1055 (473–
2076) 
607 (269–1872) 0.154 
    Creatinine, mg/dl, median (IQR) 0.9 (0.2) 0.8 (0.2) 0.578 
    Hemoglobin, g/dl, mean (SD) 14.2 (0.8) 14.3 (2.1) 0.847 
    Troponin I, ng/ml, median (IQR) 25.8 (6.2–41.9) 14.6 (3.6–54.2) 0.630 
Laboratory parameters at 6 months 
    NT-proBNP, pg/ml, median (IQR) 96 (82–356) 228 (113–347) 0.207 
Echocardiography at baseline, mean (SD) 
LVEDV, ml 102.8 (27.5) 118.6 (45.6) 0.343 
LVESV, ml 53.5 (18.7) 64.7 (29.7) 0.312 
LVEF, % 48.9 (7.8) 46.2 (8.9) 0.823 
Echocardiography at 6 months, mean (SD) 
LVEDV, ml 152.7 (46.9) 115.5 (31.7) 0.043 
LVESV, ml 65.3 (28.1) 56.3 (25.3) 0.350 
     LVEF, % 57.8 (8.5) 52.5 (8.8) 0.393 
Pharmacotherapy at discharge, n (%) 




    P2Y12 inhibitor 17 (100) 54 (100) 1.00 
    Statin 17 (100) 53 (98) 0.57 
    β-blocker 15 (88) 52 (96) 0.21 
    ACE-inhibitor or ARB 16 (94) 53 (98) 0.38 
    Aldosterone receptor antagonist 2 (1) 5 (10) 0.76 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers; 
BMI, body mass index — weight in kilograms divided by square of the height in meters; IQR, 
interquartile range; LVEDV, left ventricle end-diastolic volume; LVEF, left ventricle ejection 
fraction; LVESV, left ventricle end-systolic volume; NT-proBNP, N-terminal pro-B-type 
















0.04 <75.3 NU 71% 67% 
Abbreviations: AUC, area under the curve; CI, confidence interval; NU, normalized units; 









Table 4. Results of univariable logistic regression analysis for prediction of LVR including pre-
operative VCAN expression transcript above the cut-off value and clinical risk factors 
Variable OR 95% CI P-value 
 
 Lower Upper  
VCAN <75.3 NU AUC  4.050 1.204 13.619 0.024 
Age 0.944 0.892 0.999 0.047 
Gender (female) 3.250 0.648 16.301 0.152 
BMI 1.082 0.935 1.252 0.292 
Anterior AMI 2.417 0.648 9.015 0.189 
Arterial hypertension 1.417 0.367 5.473 0.613 
Diabetes mellitus 1.033 0.233 4.578 0.966 
Dyslipidemia 2.885 0.556 14.957 0.207 
Smoking 0.952 0.263 3.448 0.941 
Previous AMI 1.773 0.147 21.423 0.652 
NT-proBNP 1.000 0.999 1.000 0.316 
Creatinine 1.000 0.999 1.001 0.763 
Hemoglobin 1.048 0.657 1.672 0.843 
Troponin I 0.996 0.982 1.010 0.571 
LVEDV 0.992 0.972 1.012 0.421 
LVESV 0.988 0.958 1.018 0.437 
LVEF 0.997 0.936 1.063 0.935 
Aspirin 1.000 0.999 1.000 0.678 
P2Y12 inhibitor 3.621 0.726 18.066 0.117 
Statin 1.000 0.999 1.000 0.520 
β-blocker 722.712 0.001 2347.72 0.999 
ACE-inhibitor or ARB 686.576 0.001 6852.21 0.999 
Aldosterone receptor antagonist 0.182 0.022 1.533 0.117 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers; 
AUC, area under the curve; BMI, body mass index — weight in kilograms divided by square 
of the height in meters; CI, confidence interval; LVEDV, left ventricle end-diastolic volume; 
LVEF, left ventricle ejection fraction; LVESV, left ventricle end-systolic volume; NT-proBNP, 





Table 5. Multivariable logistic regression model for prediction of LVR including significant 
predictors of LVR in univariable analysis (pre-operative VCAN expression transcript above the 
cut-off value and age) 
Variable OR 95% CI P-value 
    Lower Upper   
VCAN <75.3 NU AUC 3.475 1.000 12.075 0.047 
Age 0.951 0.897 1.009 0.099 
Abbreviations: AUC, area under the curve; CI, confidence interval; NU, normalized units; OR, 













Figure 2. A. Messenger RNA transcript expression levels measured at baseline after acute 
myocardial infarction (AMI) in patients with or without left ventricle remodeling (LVR) at 6 
months follow-up. Data are expressed as median and interquartile range and compared using 
Mann-Whitney U test. B. Receiver operating characteristic curve showing versican (VCAN) 
expression after AMI to predict LVR. C. Correlation between VCAN expression measured at 
baseline and NTproBNP concentration measured at baseline and 6 months after AMI, analyzed 
using Spearman correlation coefficient test. D. Correlation between VCAN expression 
measured at baseline and LVEF at baseline and 6 months after AMI, analyzed using Spearman 
correlation coefficient test 
 
